Rapport Therapeutics, Inc. Common Stock
RAPPNASDAQHealthcare● Active
$36.68
+$0.58(+1.61%)
Market Cap$1.3B
P/E Ratio—
52W High$42.269
52W Low$10.505
Rapport Therapeutics, Inc. Common Stock（RAPP）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RAPP · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — |
| Operating Expenses | ||||
| R&D Expenses | $0.09B | $0.06B | $0.03B | $0.01B |
| G&A Expenses | $0.03B | $0.02B | $0.01B | $0.00B |
| Total Operating Expenses | $0.13B | $0.08B | $0.04B | $0.01B |
| Operating Income | ($0.13B) | ($0.08B) | ($0.04B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.08B) | ($0.03B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.11B) | ($0.08B) | ($0.03B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-2.86 | $-3.78 | $-0.95 | $-0.29 |
| Wtd Avg Shares | 0.05B | 0.02B | 0.02B | 0.02B |
| EBITDA | ($0.12B) | ($0.08B) | ($0.03B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Rapport Therapeutics, Inc. Common Stock
关于Rapport Therapeutics, Inc. Common Stock（RAPP）损益表
Rapport Therapeutics, Inc. Common Stock（RAPP）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，RAPP实现营收$0.00B，毛利润($0.00B)（毛利率—），净利润($0.11B)（净利率—）。
常见问题
RAPP · 4 问Rapport Therapeutics, Inc. Common Stock（RAPP）2025财年营收为$0.00B，同比down—%。
RAPP revenueRAPP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08